Enliven Therapeutics (ELVN) Stock News

Enliven Therapeutics (Nasdaq: ELVN) reported Q3 2025 results and a clinical update on Nov 12, 2025. Key highlights: completed dosing in the randomized Phase 1b cohorts of the ENABLE trial for ELVN-001 in CML and remains on track to initiate a global Phase 3 pivotal trial in 2026. Management presented ENABLE data at multiple international meetings and will present additional subset data at ASH 2025 on Dec 7, 2025. Financials: cash, cash equivalents and marketable securities of $477.6M, expected to provide runway into the first half of 2029. Q3 operating figures: R&D $18.2M, G&A $6.9M, net loss $20.1M.

Enliven Therapeutics (Nasdaq: ELVN) will present preliminary Phase 1a/1b ENABLE data on ELVN-001 in chronic myeloid leukemia patients with atypical BCR::ABL1 fusion transcripts at ASH 2025 (Dec 6-9).

As of Apr 28, 2025 six previously treated chronic phase CML patients with atypical transcripts received ELVN-001 (20–80 mg BID; some escalated to 120 mg QD). Four patients were efficacy-evaluable and showed transcript reductions including multiple >1 log decreases, a fall from 0.95% to 0.15%, and durable on-study durations (80–505 days). No treatment-emergent adverse events >Grade 2 were reported in these patients. Presentation details: poster session Dec 7, 6:00–8:00 p.m. ET.

Enliven Therapeutics (Nasdaq: ELVN) announced upcoming presentations of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting. The trial focuses on ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated Chronic Myeloid Leukemia.

The data will be presented in both oral and poster formats by Dr. Michael J. Mauro on September 3-4, 2025, at the George R. Brown Convention Center in Houston. This presentation is an encore of previously presented data at the European Hematology Association (EHA) 2025 Congress.

Enliven Therapeutics (Nasdaq: ELVN) reported significant progress in Q2 2025, highlighted by positive Phase 1 clinical trial results for ELVN-001 in chronic myeloid leukemia (CML) treatment. The trial demonstrated a 47% cumulative MMR rate, with 32% of patients achieving MMR by 24 weeks, surpassing historical data from competitor treatments.

The company strengthened its financial position through a $230 million public offering, ending Q2 with $490.5 million in cash and equivalents, extending runway into H1 2029. Quarterly financials showed R&D expenses of $21.5 million and a net loss of $25.3 million. Enliven plans to initiate a Phase 3 pivotal trial in 2026.

Enliven Therapeutics (Nasdaq: ELVN) has successfully closed its public offering, raising approximately $230 million in gross proceeds. The offering included 9,920,987 shares of common stock at $19.66 per share, including the full exercise of the underwriters' option for 1,526,250 additional shares. Additionally, the company issued pre-funded warrants to purchase 1,780,263 shares at $19.659 per warrant. The offering was managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho as joint book-running managers, with LifeSci Capital acting as lead manager. The securities were offered through a Registration Statement on Form S-3 and related filings with the SEC.

Enliven Therapeutics (ELVN) has announced the pricing of its public offering, consisting of 8,394,737 shares of common stock at $19.66 per share and pre-funded warrants for up to 1,780,263 shares at $19.659 per warrant. The gross proceeds are expected to be approximately $200 million before deducting expenses. The offering is set to close around June 16, 2025. The company has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in common stock. The offering is being managed by joint book-runners Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital as lead manager. The offering will be made through a Registration Statement on Form S-3 and is subject to market conditions and regulatory approval.

Enliven Therapeutics (NASDAQ: ELVN) reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) at EHA 2025. The trial showed a 47% cumulative MMR rate by 24 weeks, with 32% achieving and 100% maintaining MMR. Among 90 enrolled patients with median treatment of 29 weeks, 67% received three or more prior TKIs. ELVN-001 demonstrated favorable safety with only 3.4% dose reductions and 4.6% discontinuations due to adverse events. The drug showed promising efficacy in heavily pretreated patients, including those resistant to prior therapies, with MMR rates comparing favorably to historical data. The pharmacokinetic profile supports once-daily dosing, and no maximum tolerated dose was reached. Enliven plans to initiate a head-to-head Phase 3 pivotal trial in 2026.

Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:

• TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
• Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
• Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET

All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.